Table 1. Univariate analysis of factors associated with hepatic steatosis.
| All patients(N = 1018) | Steatosis (−) (n = 563) | Steatosis (+) (n = 455) | P value | |
|---|---|---|---|---|
| Age (years, mean + SD) | 51.8 + 11.3 | 50.9 + 11.8 | 53.0 + 10.6 | 0.004 |
| Male gender, n (%) | 576 (56.6) | 318 (56.5) | 258 (56.7) | 0.94 |
| BMI (kg/m2, mean + SD) | 24.9 + 3.5 | 24.3 + 3.5 | 25.7 + 3.4 | <0.001 |
| BMI, <18.5, 18.5–24, 24–27, 27–30,>30 (kg/m2, %) | 1.9%, 39.8%, 33.5%, 16.8%, 8.1% | 3.2%, 46.5%, 29.8%, 14.6%, 5.9% | 0.2%, 31.4%, 38.0%, 19.6%, 10.8% | <0.001 |
| Diabetes, n (%) | 158 (15.5) | 72 (12.8) | 86 (18.9) | 0.007 |
| Cholesterol (mg/dL, mean + SD)* | 167 + 33 | 167 + 33 | 166 + 34 | 0.53 |
| Triglyceride (mg/dL, mean + SD)* | 103 + 57 | 109 + 64 | 96 + 49 | 0.004 |
| Platelet count (x103u/L, mean + SD) | 164 + 58 | 165 + 56 | 162 + 59 | 0.44 |
| AST (IU/L,mean + SD ) | 104 + 62 | 104 + 67 | 103 + 54 | 0.96 |
| ALT (IU/L,mean + SD) | 157 + 103 | 159 + 114 | 155 + 86 | 0.58 |
| Ferritin(ng/ml, mean + SD) | 406 + 472 | 400 + 554 | 415 + 344 | 0.61 |
| r-GT (U/L,mean + SD) | 67.2 + 63.3 | 62.3 + 62.5 | 73.4 + 63.7 | 0.005 |
| HCV genotype 1, n/N (%) (N = 1012) | 604/1012 (59.7) | 344/562 (61.2) | 260/450 (59.5) | 0.27 |
| HCV RNA (log IU/mL, mean + SD) | 5.38 + 0.98 | 5.37 + 1.03 | 5.39 + 0.92 | 0.81 |
| HBsAg(+), n (%) | 90 (8.8) | 53 (9.4) | 37 (8.1) | 0.47 |
| Fibrosis 3-4, n (%) | 308 (30.3) | 162 (28.8) | 146 (32.1) | 0.25 |
| PNPLA3 rs738409 genotype | ||||
| CC/CG/GG, n (%) | 422 (41.5)/ 477 46.9)/ 119 (11.7) | 247 (43.9)/ 272 (48.3)/ 44 (7.8) | 175 (38.5) / 205 (45.1)/75 (16.5) | <0.001 |
| Recessive model GG, n (%) | 119 (11.7) | 44 (7.8) | 75 (16.5) | <0.001 |
| Dominant model GG+GC, n (%) | 596 (58.5) | 316 (56.1) | 280 (61.5) | 0.08 |
Note:
*data available in 694 patients. BMI: body mass index; rGT: r-glutamyltransferase; AST: alanine aminotransferase; ALT: aspartate aminotransferase; HBsAg: hepatitis B surface antigen; PNPLA3: patatin-like phospholipase domain-containing 3.